NCT01254383

Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Versus To Viagra® Oral Tablet.

An Open Label Crossover Study In Healthy Older Male Subjects To Evaluate The Pharmacokinetics And Safety Of Sildenafil Following Fasted Administration Of An Orally Disintegrating Tablet Formulation Of Sildenafil Administered With Or Without Water Relative To Viagra® Oral Tablet With Water

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: Male
• Age: 45 Years
• Healthy volunteers: Accepted

Summary

This study will evaluate if an orally disintegrating tablet of sildenafil will have similar pharmacokinetic properties as the conventional tablet of sildenafil.

Conditions

• Erectile Dysfunction

Interventions

Type	Name	Description
DRUG	Sildenafil Tablet	Tablet, 50 mg, Single Dose
DRUG	Sildenafil ODT	Orally Disintegrating Tablet, 50 mg, Single Dose
DRUG	Sildenafil ODT	Orally Disintegrating Tablet, 50 mg, Single Dose

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2010-12-06
• Last updated: 2021-02-01

Locations

1 site across 1 country: Singapore